Oral Cancer News – Page 139 – The Oral Cancer Foundation News Archive

Lower radiation reduces xerostomia in head/neck cancer patients

Source: www.drbicuspid.com Author: DrBicuspid Staff Lowering the radiation dose to the submandibular gland of patients with head and neck cancer decreases xerostomia, according to a study presented on April 20 at the European Society for Radiotherapy and Oncology (ESTRO) meeting in Geneva. Radiation oncologists at University Medical Center Utrecht (UMCU) showed for the first time that it is possible to reduce xerostomia in patients treated with radiotherapy for head and neck cancer if the radiation dose to a salivary gland (the submandibular gland) on the opposite side to the tumor is minimized, stated a university press release. It is the largest study yet to show a correlation between radiation doses to the submandibular glands and their output of saliva. Guidelines for the recommended maximum dose could potentially be issued for use in clinical practice to benefit patients, according to the researchers. Approximately 40% of head and neck cancer patients suffer from xerostomia in the long term, which causes problems with eating, sleeping, speech, tooth loss, and oral hygiene, leading to diminished quality of life, social isolation, and difficulty in the ability to work. Attempts to treat xerostomia and its consequences can be costly and are not very effective, the study noted. Therefore, the UMCU researchers looked at using intensity-modulated radiotherapy (IMRT) to treat the tumors and spare the submandibular gland on the opposite side of the tumor and both parotid glands. They also wanted to determine the maximum radiation dose and how the treatment would affect patients' xerostomia. They analyzed [...]

Oral Cancer Foundation News Team - A2013-04-24T12:19:16-07:00April, 2013|Oral Cancer News|

What the ‘rinse-and-spit’ oral cancer test could mean for dental professionals and their patients

Source: www.dentistryiq.com Author: Vicki Cheeseman, Associate Editor A new oral cancer “rinse-and-spit” test for the early detection of tumors could mean great things for dental professionals and their patients when the test becomes available for use in dental practices nationwide possibly as early as late 2014 or into 2015. The test, developed at the University of Miami Miller School of Medicine and exclusively licensed to Vigilant Biosciences, Inc., will be available as a low-cost, point-of-care screening test for the early detection of oral cancer, and is envisioned as a kit with a special oral rinse and test strip. The test strip detects proteins that are markers of oral cancer and are captured by the rinse. The markers may be present before a lesion is easily visible. Early detection tests are critical because the majority of patients present in late stage when cure rates reach only 40%. I asked Dr. Franzmann to explain how the test strip works. “The beauty of the test strip approach is that it is so simple for the patient and health-care professional to use. The technology behind the test strips has been around for many years and is used for many medical applications. The key is to know what to test for. Through our research, we discovered certain proteins, or markers, are present in the saliva in the early stages of squamous cell carcinoma, the most common head and neck cancer.” How early can tumors be detected with the test strip? Dr. Franzmann said, “The tumors [...]

Oral Cancer Foundation News Team - A2013-04-24T12:13:03-07:00April, 2013|Oral Cancer News|

HPV vaccination—reaping the rewards of the appliance of science

Source: bmj.comDate: April 18, 2013By: Simon Barton, clinical director National programmes could virtually eliminate certain diseases and substantially reduce costs. The optimism generated by scientific breakthroughs often turns to disappointment when applied to the real world of clinical care. It is therefore worth celebrating the extraordinary success of Australia’s national human papillomavirus (HPV) vaccination programme, which was implemented five years ago, as reported in the linked paper by Ali and colleagues (doi:10.1136/bmj.f2032).1 This analysis of data on 85 770 new patients from six Australian sexual health clinics shows a remarkable reduction in the proportion of women under 21 years of age presenting with genital warts—from 11.5% in 2007 to 0.85% in 2011 (P<0.001). Only 13 cases of genital warts were diagnosed in women under the age of 21 across all six health clinics in 2011. Such a reduction in this distressing disease caused by a sexually transmitted virus is a major public health achievement. Furthermore, the near eradication of genital warts in young Australian women will probably have a major impact on the costs of sexual healthcare. In 2007, Australia became one of the first countries to implement a nationally funded HPV vaccination programme for girls and young women with the quadrivalent vaccine. It started with the vaccination of girls aged 12 years in schools and a catch-up programme for girls and women aged 13-26 years. Quadrivalent vaccine protects against HPV types 6 and 11, which cause more than 90% of genital warts, in addition to HPV types 16 and 18, which [...]

Charlotte Parker2013-04-22T12:13:42-07:00April, 2013|Oral Cancer News|

Robotic surgery vs. radiation, chemo for throat cancer, study to see which is best

By: Sheryl Ubelacker, The Canadian Press, April 17, 2013Source: ottawacitizen.com TORONTO - It was quite a shock for Rod Sinn when he learned the persistent sore throat he'd had for five months, initially diagnosed as tonsillitis, was actually an increasingly common form of throat cancer caused by the human papilloma virus. Equally unpleasant was the news that the standard treatment for oropharyngeal cancer, which typically affects the back of the tongue, tonsils and nearby tissues, is radiation and chemotherapy. Sinn, a physically fit non-smoker who only drinks alcohol occasionally, had seen what the double-barrelled treatment could do. A friend diagnosed with throat cancer a year earlier and given the standard treatment lost his salivary glands and sense of taste. "I thought, wait a minute, there's got to be another option. I really don't like the side-effects of all that radiation," the 52-year-old businessman, who lives in Oakville, Ont., near Toronto, said Tuesday. After searching the Internet, he discovered doctors at Western University in London, Ont., were the only ones in Canada performing robotic-assisted surgery for throat cancer. Sinn had the robotic surgery in spring 2011, plus a follow-up operation to remove some lymph nodes for testing to make sure his cancer hadn't spread. While the surgery left him unable to swallow for several weeks and he lost some taste buds for a time, he is virtually back to normal except for some numbness in his neck where the lymph nodes were removed. "It was fantastic," said Sinn, who counts himself a believer [...]

Charlotte Parker2013-04-18T16:40:32-07:00April, 2013|Oral Cancer News|

Researchers design drug to block incidence of head, neck cancer caused by HPV virus

Source: www.news-medical.net Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy. HPV-positive head and neck cancer has become three times more common since the 1970s, and it could reach epidemic levels in the future, say researchers at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) who led the study. "We believe these findings will help meet the real need for more effective and safer therapy for a growing number of HPV-positive head and neck cancer patients," says principal investigator Dr. Quintin Pan, associate professor of otolaryngology at the OSUCCC - James. The study was published in the journal Oncogene. The research, which mainly used head and neck cancer cells, shows that a protein produced by the virus blocks a protein made by the host cell. The cell protein, called p300, regulates a gene called p53. This gene both controls cell division and protects the body against cancer by causing cells to die before they become malignant.By blocking the cell protein, HPV forces the host cell to live instead of die and to proliferate and form tumors. The prospective new drug, called CH1iB, prevents the viral protein from binding with the cell protein. This restores [...]

Oral Cancer Foundation News Team - A2013-04-11T09:00:53-07:00April, 2013|Oral Cancer News|

HPV linked to certain lung cancers; is oral sex to blame?

Source: www.medicaldaily.com Author: Jonathan Weiss By now, it's a given that smoking causes lung cancer. The American Lung Association reports that 80 to 90 percent of all cases of lung cancer are smoking-related. The remaining 10 to 20 percent, though, has been more of a mystery — until now. A new line of research has implicated thye sexually transmitted infection human papillomavirus, or HPV, in lung cancers that were found in non-smokers. HPV is the leading cause of all cervical cancer cases in the world. It's a well-known disease that's gottena lot of press in recent years; an effective vaccine was recently developed that can prevent the viral infection and subsequent cervical cancer development. Whether or not the vaccine should be required for teenage girls has become a hot-button political issue. Adding fuel to the fire, a research team from the Fox Chase Cancer Center recently looked at tissue samples from lung cancer patients who had no history of smoking and saw that close to 6 percent showed evidence that they had been driven by HPV infection. Four out of 36 lung samples had signs of infection from two strains of HPV known to cause cancer. Looking more closely at the two samples infected by one strain of HPV, Dr. Ranee Mehra, MD, attending physician in medical oncology at Fox Chase and her team saw signs the virus had integrated into the tumor's DNA — which is even more suggestive that the infection had caused the tumor in the first [...]

Oral Cancer Foundation News Team - A2013-04-11T08:30:16-07:00April, 2013|Oral Cancer News|

Black raspberries reduce DNA damage in oral cancer survivors

Source: www.prweb.com Author: press release New research presented Wednesday, April 10, at the American Association for Cancer Research Annual Meeting 2013 in Washington, DC, suggests that a food-based cancer prevention study aimed at oral cancer survivors was effective at attenuating highly reactive oxygen molecules that can damage DNA and trigger cancer. In the study, a phase 1b clinical trial conducted at The Ohio State University, participants consumed 4 - 8 grams of black raspberries daily for six months. The berries were well tolerated by the participants and adherence to the regimen was good. This study provides compelling data that indicate biochemical markers of cancer-causing DNA damage were reduced in participants who adhered to the food-based regimen and supports other evidence from a phase 2 human trial linking application of black raspberry gel to precancerous lesions to a reduced risk of developing oral cancer. Black raspberries, not to be confused with blackberries, are almost exclusively grown in Oregon, on the west coast of the United States. They have been studied extensively because of their high concentration of certain phytonutrients and antioxidants. BerriProducts, an Oregon-based company, has been supplying black raspberry products to research universities across the country for the last four years.

Oral Cancer Foundation News Team - A2013-04-11T08:20:55-07:00April, 2013|Oral Cancer News|

Study shows Vigilant Biosciences’ simple “rinse and spit” test effective in detecting oral cancer

Source: www.marketwatch.com Author: press release A new "rinse and spit" test for oral cancer is capable of early detection of tumors across "a racially and ethnically diverse population," according to results of a study conducted by the University of Miami Miller School of Medicine. Coinciding with Oral Cancer Awareness month, results from the largest oral cancer marker study of its kind in the U.S. were presented at the annual meeting of the American Association for Cancer Research in Washington, D.C. and the American Head and Neck Society annual meeting in Orlando, Florida. The test, developed at the University of Miami Miller School of Medicine and exclusively licensed to Vigilant Biosciences, Inc. (Vigilant), will be available as a low-cost, point-of-care "rinse and spit" screening test for the early detection of oral cancer. The study of 300 subjects, sponsored by the National Cancer Institute, employed a case-control design ensuring cases (oral cancer patients) and controls (volunteers without cancer) were similar with respect to other important factors such as tobacco and alcohol use, age and race. The study was conducted by principal investigator Elizabeth Franzmann, M.D., Associate Professor of Otolaryngology, at the University of Miami Miller School of Medicine and a member of the University's Sylvester Comprehensive Cancer Center. "There is a tremendous need for a simple and painless test for early detection of oral cancer because the majority of patients present in late stage when cure rates reach only 40 percent," said Dr. Franzmann. "Since minority patients and those of low socioeconomic [...]

Oral Cancer Foundation News Team - A2013-04-11T08:14:23-07:00April, 2013|Oral Cancer News|

Researchers Design Drug to Restore Cell Suicide in HPV-Related Head and Neck Cancer

Source: sciencedaily.comDate: April 8, 2013 Researchers have discovered a new mechanism by which the human papilloma virus (HPV) causes head and neck cancer, and they have designed a drug to block that mechanism. Though further research is needed, the new agent might offer a safer treatment for these tumors when combined with a tapered dose of standard chemotherapy. HPV-positive head and neck cancer has become three times more common since the 1970s, and it could reach epidemic levels in the future, say researchers at the Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC -- James) who led the study. "We believe these findings will help meet the real need for more effective and safer therapy for a growing number of HPV-positive head and neck cancer patients," says principal investigator Dr. Quintin Pan, associate professor of otolaryngology at the OSUCCC -- James. The study was published in the journal Oncogene. The research, which mainly used head and neck cancer cells, shows that a protein produced by the virus blocks a protein made by the host cell. The cell protein, called p300, regulates a gene called p53. This gene both controls cell division and protects the body against cancer by causing cells to die before they become malignant. By blocking the cell protein, HPV forces the host cell to live instead of die and to proliferate and form tumors. The prospective new drug, called CH1iB, prevents the viral protein from binding [...]

Charlotte Parker2013-04-09T15:09:21-07:00April, 2013|Oral Cancer News|

Dental groups dispute Consumer Reports cancer screening story

Source: http://www.drbicuspid.comBy: Donna Domino, Features EditorDate: April 5, 2013 The dental community is up in arms over a recent Consumer Reports article that claims oral cancer screening is one of several medical tests that are overrecommended and unnecessary for all but high-risk patients. The article, which appears in the March 2013 issue, concluded that "most people shouldn't waste their time" on most diagnostic tests, including chairside visual screenings for oral cancer. "Most people don't need the test unless they are at high risk, because the cancer is relatively uncommon," Consumer Reports wrote. But the ADA and the Oral Cancer Foundation vehemently disagree with the magazine's conclusions, asserting that visual screening can result in earlier diagnosis of oral cancer and other oral diseases. The Consumer Reports article recommends only three cancer tests -- cervical, colon, and breast -- as worthwhile, and includes oral cancer screening among "eight to avoid" tests: ovarian, pancreatic, testicular, prostate, bladder, lung, oral cavity, and skin cancer. The magazine said its ratings were based mainly on reviews from the U.S. Preventive Services Task Force. Early diagnosis critical According to Consumer Reports, the medical community has "systematically exaggerated" the benefits of screening while downplaying the harms, such as unnecessary radiation and biopsies. The ADA quickly registered its disappointment with the recommendations and sent a letter -- co-signed by the American Academy of Oral & Maxillofacial Pathology -- to the editors of Consumer Reports, noting that noninvasive visual and tactile oral cancer screenings are typically included in oral exams [...]

Charlotte Parker2013-04-23T15:24:32-07:00April, 2013|OCF In The News, Oral Cancer News|